Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 6.93 | 7.13 | 0.20 |
Stocks | 91.08 | 91.08 | 0.00 |
Preferred | 1.99 | 1.99 | 0.00 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 16.87 | 14.59 |
Price to Book | 2.08 | 2.06 |
Price to Sales | 1.45 | 1.21 |
Price to Cash Flow | 10.55 | 9.20 |
Dividend Yield | 2.19 | 2.13 |
5 Years Earnings Growth | 10.42 | 10.23 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 27.12 | 10.14 |
Consumer Defensive | 21.04 | 6.58 |
Industrials | 19.57 | 16.54 |
Utilities | 17.48 | 7.04 |
Financial Services | 10.03 | 17.62 |
Technology | 2.83 | 11.06 |
Real Estate | 1.38 | 7.69 |
Consumer Cyclical | 0.55 | 11.55 |
Number of long holdings: 56
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Dentsply | US24906P1093 | 7.03 | 18.12 | -3.87% | |
Henkel AG & Co KGAA | US42550U1097 | 5.80 | 18.95 | -1.10% | |
Qiagen NV | NL0015001WM6 | 5.14 | - | - | |
Northern Trust | US6658591044 | 4.06 | 99.46 | -2.70% | |
Henry Schein | US8064071025 | 4.02 | 69.67 | -1.96% | |
Werner | US9507551086 | 3.97 | 34.46 | -2.82% | |
Envista Holdings | US29415F1049 | 3.87 | 18.58 | -3.08% | |
United Utilities ADR | US91311E1029 | 3.84 | 23.59 | -3.60% | |
Clorox | US1890541097 | 3.83 | 157.57 | -1.90% | |
Globe Life | US37959E1029 | 3.28 | 112.42 | -1.49% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Nuance Concentrated Value Instituti | 151.1M | 6.18 | 3.55 | 7.03 | ||
Nuance Mid Cap Value Fund Investor | 27.7M | 5.37 | 2.11 | 7.88 | ||
Nuance Concentrated Value Investor | 8.58M | 5.87 | 3.27 | 6.73 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review